Table 4 Incidence (any grade) of adverse events of special interest

From: Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer

Incidence, %

Patients with liver metastases

Patients without liver metastases

 

AA+ P (n=88)

P (n=28)

AA+ P (n=703)

P (n=366)

Fluid retention/edema

36.4

28.6

32.6

23.5

LFT abnormalitiesa

19.3

14.3

10.2

8.5

Cardiac disorders

15.9

7.1

15.9

12.0

Hypokalemia

15.9

7.1

18.3

9.3

Hypertension

3.4

0

12.1

8.7

  1. Abbreviations: AA, abiraterone acetate; LFT, liver function test; P, prednisone.
  2. aHigher incidence of LFT abnormalities is to be expected in patients with liver involvement.
Back to article page